rmdopen.bmj4d
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated ...
rmdopen.bmj4d
From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?
It is believed that therapy for rheumatoid arthritis (RA) is the most effective and beneficial within a short time frame around RA diagnosis. This insight has caused a shift from research in patients ...
rmdopen.bmj10d
Novel insight into the aetiology of rheumatoid arthritis gained by a cross-tissue transcriptome-wide association study
Background Although genome-wide association studies (GWASs) have identified more than 100 loci associated with rheumatoid arthritis (RA) susceptibility, the causal genes and biological mechanisms ...
rmdopen.bmj12d
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines
Background The current standard of care in rheumatoid arthritis (RA) requires regular assessment of disease activity (DA). All standard RA DA measurement instruments require joint counts to be ...
rmdopen.bmj12d
Patient-reported outcome measures in osteoarthritis: a systematic search and review of their use and psychometric properties
Introduction Patient-reported outcome measures (PROM) or self-completed questionnaires have been used to report outcomes in osteoarthritis (OA) for over 35 years. Choices will always need to be made ...
rmdopen.bmj23d
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
Immunomodulatory therapy for rheumatoid arthritis (RA) carries risk for infectious complications. Understanding the risks of different therapeutic options is essential for making treatment decisions ...
rmdopen.bmj29d
Primary Sjögren’s syndrome independently promotes premature subclinical atherosclerosis
Objectives Cardiovascular comorbidities are common in patients with autoimmune diseases. This study investigates the extent of subclinical atherosclerosis in patients with primary Sjögren’s syndrome ...
rmdopen.bmj1mon
Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study
Objectives To identify serious infection (SI) risk by aetiology and site in patients with rheumatoid arthritis (RA) compared with those with non-inflammatory rheumatic and musculoskeletal diseases ...
rmdopen.bmj1mon
Development, usability and acceptability of an integrated eHealth system for spondyloarthritis in the Netherlands (SpA-Net)
Objective To develop and test the usability and acceptability of a disease-specific integrated electronic health (eHealth) system for spondyloarthritis (SpA) in the Netherlands (‘SpA-Net’). Methods ...
rmdopen.bmj1mon
Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease
3 Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le Scotte, University of Siena, Siena, Italy Blau syndrome (BS) and early-onset ...
rmdopen.bmj2mon
Acetylated bacterial proteins as potent antigens inducing an anti-modified protein antibody response
Objective Gut-residing bacteria, such as Escherichia coli, can acetylate their proteome under conditions of amine starvation. It is postulated that the (gut) microbiome is involved in the breach of ...
rmdopen.bmj2mon
Undifferentiated connective tissue disease: state of the art on clinical practice guidelines
The term ‘undifferentiated connective tissue disease’ (UCTD) is generally used to describe clinical entities characterised by clinical and serological manifestations of systemic autoimmune diseases ...